In the last 4 weeks the Fresenius stock has climbed around 13 percent. On the one hand, the latest quarterly figures – for the first time without the inclusion of Fresenius Medical Care (FMC) – have convinced. On the other hand, most analysts also see potential in the DAX paper.

In the short term, the title has the mark of 30 euros in its sights. But there are also several aspects that speak for a positive development of the Fresenius share in the medium and long term. The company is trying to modernize its structure in order to be able to return to the solid successes of the past.

Fresenius with very decent quarterly figures In the summer, Fresenius decided to reform the corporate structure and make the dialysis subsidiary Fresenius Medical Care (FMC) independent. On the one hand, the legal form was rather complicated, on the other hand FMC has increasingly burdened the balance sheet of the parent company. In the 3rd quarter of 2023, Fresenius published figures for the first time without the dialysis subsidiary.

In the months of July to the end of September, sales of 5.52 billion euros were achieved – an increase of 2 percent (currency-adjusted 6 percent) compared to the previous year. The adjusted EBIT increased by 8 percent to 519 million euros, the margin was accordingly 9.4 percent.

Fresenius raised its outlook for the current fiscal year 2023 after the Q3 figures: While sales are expected to continue to grow in the mid-single digits, EBIT is now expected to be approximately at the same level as last year. Before the figures were released, a slight decrease was expected.

Fresenius share: Optimism among analysts With the decent figures and the new structure, Fresenius goes into the last quarter of the year in a strengthened position. In the short term, no miracles are to be expected with the Fresenius share. The mark of 30 euros was last broken in September and could soon fall again. In the medium and long term, the share speaks for itself, as it is still by no means too expensive and there is still more potential after the price decline of the last few years (in 2017 the title was still quoted above 70 euros).

Most analysts are also generally positive and often see targets for the Fresenius share between 30 and 40 euros. Jefferies recently confirmed its target price of 41 euros and JPMorgan raised its target from 29.60 to 32.50 euros. Investors with a longer time horizon should now have the Fresenius share back on their list.